EMSA with WT PUF60 confirmed strong binding to a positive control derived from AdML [11] and showed reduced binding of each cancer-associated RRM mutation that produced trans-acting defects (Figure 7A; Table 1). The gene discussed is PUF60; the disease is cancer.